FDA SADR Rule Would Expedite Congenital Anomaly Reports, FDAer Says

FDA's proposed rule on the reporting of postmarketing adverse events would require that spontaneous reports of congenital anomalies always be expedited to the agency, FDA Pregnancy Labeling Task Force Project Manager Dianne Kennedy said Jan. 9.